The patent also provides for a method to automatically release all applied pressure to the atmosphere in the event of a system or power failure as a safety measure to avoid injury to the patient. According to the company, at the start of treatment, the therapist selects the optimal inflation pressure for the patient to comfortably receive effective therapy, the technology then fully controls and maintains, with accuracy, the proper inflation and deflation pressures throughout the treatment.
John Hui, president and CEO of Vasomedical and inventor of the patent, said: “Control and maintenance of optimal pressure during enhanced external counterpulsation (EECP) treatment is essential to the effectiveness of this therapy for the high percentage of patients that may have irregular or premature heart beats. This patent is critical to our ability to produce a completely automatic EECP therapeutic system which is capable of providing maximal safety and effectiveness to patients.”